{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:00:00Z","timestamp":1740124800659,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["5T32HL007734","R01HL021796","R01HL086741","5T32HL007734","5T35HL110843","R01HL021796","R01HL086741","5T32HL007734","5T35HL110843"],"award-info":[{"award-number":["5T32HL007734","R01HL021796","R01HL086741","5T32HL007734","5T35HL110843","R01HL021796","R01HL086741","5T32HL007734","5T35HL110843"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1038\/s41434-024-00460-2","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T12:02:10Z","timestamp":1721131330000},"page":"467-476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of heparin and direct thrombin inhibitors on cell-penetrating polymer siRNA transfection"],"prefix":"10.1038","volume":"31","author":[{"given":"Lucas","family":"Mota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3533-7028","authenticated-orcid":false,"given":"Max","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John N.","family":"Tomeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melina","family":"Recarey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nyah","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leena","family":"Pradhan-Nabzdyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank W.","family":"LoGerfo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8041-120X","authenticated-orcid":false,"given":"Patric","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"460_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114432","volume":"189","author":"MM Zhang","year":"2021","unstructured":"Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong XB. The growth of siRNA-based therapeutics: Updated clinical studies. Biochem Pharmacol. 2021;189:114432.","journal-title":"Biochem Pharmacol"},{"key":"460_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11427-018-9438-y","volume":"63","author":"PE Saw","year":"2020","unstructured":"Saw PE, Song EW. siRNA therapeutics: a clinical reality. Sci China Life Sci. 2020;63:485\u2013500.","journal-title":"Sci China Life Sci"},{"key":"460_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jconrel.2017.12.001","volume":"270","author":"P Jaiprasart","year":"2018","unstructured":"Jaiprasart P, Yeung BZ, Lu Z, Wientjes MG, Cui M, Hsieh CM, et al. Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. J Control Release. 2018;270:101\u201313.","journal-title":"J Control Release"},{"key":"460_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.bbrc.2012.07.078","volume":"425","author":"CS Nabzdyk","year":"2012","unstructured":"Nabzdyk CS, Chun M, Pradhan Nabzdyk L, Yoshida S, LoGerfo FW. Differential susceptibility of human primary aortic and coronary artery vascular cells to RNA interference. Biochem Biophys Res Commun. 2012;425:261\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"460_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-48","volume":"9","author":"CS Nabzdyk","year":"2011","unstructured":"Nabzdyk CS, Chun M, Pradhan L, Logerfo FW. High throughput RNAi assay optimization using adherent cell cytometry. J Transl Med. 2011;9:48.","journal-title":"J Transl Med"},{"key":"460_CR6","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1016\/j.biomaterials.2013.12.026","volume":"35","author":"CS Nabzdyk","year":"2014","unstructured":"Nabzdyk CS, Chun MC, Oliver-Allen HS, Pathan SG, Phaneuf MD, You JO, et al. Gene silencing in human aortic smooth muscle cells induced by PEI-siRNA complexes released from dip-coated electrospun poly(ethylene terephthalate) grafts. Biomaterials. 2014;35:3071\u20139.","journal-title":"Biomaterials"},{"key":"460_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jamcollsurg.2006.12.029","volume":"204","author":"ND Andersen","year":"2007","unstructured":"Andersen ND, Monahan TS, Malek JY, Jain M, Daniel S, Caron LD, et al. Comparison of gene silencing in human vascular cells using small interfering RNAs. J Am Coll Surg. 2007;204:399\u2013408.","journal-title":"J Am Coll Surg"},{"key":"460_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-1-4939-9686-5_7","volume":"2040","author":"B Cinquin","year":"2019","unstructured":"Cinquin B, Lopes F. Structure and fluorescence intensity measurements in biofilms. Methods Mol Biol. 2019;2040:117\u201333.","journal-title":"Methods Mol Biol"},{"key":"460_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1177\/1076029610382651","volume":"17","author":"B Ivandic","year":"2011","unstructured":"Ivandic B, Zorn M. Monitoring of the anticoagulants argatroban and lepirudin: a comparison of laboratory methods. Clin Appl Thromb Hemost. 2011;17:549\u201355.","journal-title":"Clin Appl Thromb Hemost"},{"key":"460_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12871-018-0475-y","volume":"18","author":"M Beiderlinden","year":"2018","unstructured":"Beiderlinden M, Werner P, Bahlmann A, Kemper J, Brezina T, Schafer M, et al. Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial. BMC Anesthesiol. 2018;18:18.","journal-title":"BMC Anesthesiol"},{"key":"460_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1051\/ject\/200537296","volume":"37","author":"JJ Veale","year":"2005","unstructured":"Veale JJ, McCarthy HM, Palmer G, Dyke CM. Use of bivalirudin as an anticoagulant during cardiopulmonary bypass. J Extra Corpor Technol. 2005;37:296\u2013302.","journal-title":"J Extra Corpor Technol"},{"key":"460_CR12","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S0022-5223(94)70150-4","volume":"108","author":"GJ Despotis","year":"1994","unstructured":"Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg. 1994;108:1076\u201382.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"460_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1191\/0267659103pf672oa","volume":"18","author":"PD Raymond","year":"2003","unstructured":"Raymond PD, Ray MJ, Callen SN, Marsh NA. Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time. Perfusion. 2003;18:269\u201376.","journal-title":"Perfusion"},{"key":"460_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1261\/rna.352507","volume":"13","author":"LM Aleman","year":"2007","unstructured":"Aleman LM, Doench J, Sharp PA. Comparison of siRNA-induced off-target RNA and protein effects. RNA. 2007;13:385\u201395.","journal-title":"RNA"},{"key":"460_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/978-1-4939-7471-9_16","volume":"1706","author":"H Han","year":"2018","unstructured":"Han H. RNA interference to knock down gene expression. Methods Mol Biol. 2018;1706:293\u2013302.","journal-title":"Methods Mol Biol"},{"key":"460_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ejpb.2018.11.005","volume":"133","author":"MJR Ruigrok","year":"2018","unstructured":"Ruigrok MJR, Xian JL, Frijlink HW, Melgert BN, Hinrichs WLJ, Olinga P. siRNA-mediated protein knockdown in precision-cut lung slices. Eur J Pharm Biopharm. 2018;133:339\u201348.","journal-title":"Eur J Pharm Biopharm"},{"key":"460_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","volume":"28","author":"MJ Koren","year":"2022","unstructured":"Koren MJ, Moriarty PM, Baum SJ, Neutel J, Hernandez-Illas M, Weintraub HS, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med. 2022;28:96\u2013103.","journal-title":"Nat Med"},{"key":"460_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41\u201351.","journal-title":"N Engl J Med"},{"key":"460_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1096\/fj.201600501r","volume":"31","author":"TC Bodewes","year":"2017","unstructured":"Bodewes TC, Johnson JM, Auster M, Huynh C, Muralidharan S, Contreras M, et al. Intraluminal delivery of thrombospondin-2 small interfering RNA inhibits the vascular response to injury in a rat carotid balloon angioplasty model. FASEB J. 2017;31:109\u201319.","journal-title":"FASEB J"},{"key":"460_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020609","volume":"10","author":"J Singh","year":"2021","unstructured":"Singh J, Kassis N, Ahuja KR, Sheth C, Verma BR, Saxena S, et al. Percutaneous coronary intervention outcomes based on decision-making capacity. J Am Heart Assoc. 2021;10:e020609.","journal-title":"J Am Heart Assoc"},{"key":"460_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/CRD.0000000000000261","volume":"28","author":"D Collins","year":"2020","unstructured":"Collins D, Goldberg S. Care of the post-CABG patient. Cardiol Rev. 2020;28:26\u201335.","journal-title":"Cardiol Rev"},{"key":"460_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jvs.2009.01.035","volume":"50","author":"PP Goodney","year":"2009","unstructured":"Goodney PP, Beck AW, Nagle J, Welch HG, Zwolak RM. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009;50:54\u201360.","journal-title":"J Vasc Surg"},{"key":"460_CR23","first-page":"41","volume":"4","author":"MS Conners 3rd","year":"2002","unstructured":"Conners MS 3rd, Money SR. The new heparins. Ochsner J. 2002;4:41\u20137.","journal-title":"Ochsner J"},{"key":"460_CR24","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2165\/00003495-200161040-00005","volume":"61","author":"K McKeage","year":"2001","unstructured":"McKeage K, Plosker GL. Argatroban. Drugs. 2001;61:515\u201322.","journal-title":"Drugs"},{"key":"460_CR25","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1517\/14656566.6.8.1349","volume":"6","author":"TE Warkentin","year":"2005","unstructured":"Warkentin TE, Koster A. Bivalirudin: a review. Expert Opin Pharmacother. 2005;6:1349\u201371.","journal-title":"Expert Opin Pharmacother"},{"key":"460_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1586\/ehm.10.53","volume":"3","author":"WP Jeske","year":"2010","unstructured":"Jeske WP, Fareed J, Hoppensteadt DA, Lewis B, Walenga JM. Pharmacology of argatroban. Expert Rev Hematol. 2010;3:527\u201339.","journal-title":"Expert Rev Hematol"},{"key":"460_CR27","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","volume":"51","author":"S Kim","year":"2023","unstructured":"Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2023 update. Nucleic Acids Res. 2023;51:D1373\u2013D80.","journal-title":"Nucleic Acids Res"},{"key":"460_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1146\/annurev.med.042808.171814","volume":"61","author":"GM Arepally","year":"2010","unstructured":"Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. Annu Rev Med. 2010;61:77\u201390.","journal-title":"Annu Rev Med"},{"key":"460_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/17474086.2021.1905512","volume":"14","author":"AM Hvas","year":"2021","unstructured":"Hvas AM, Favaloro EJ, Hellfritzsch M. Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment. Expert Rev Hematol. 2021;14:335\u201346.","journal-title":"Expert Rev Hematol"},{"key":"460_CR30","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1001\/archinte.163.15.1849","volume":"163","author":"BE Lewis","year":"2003","unstructured":"Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG, Argatroban I. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849\u201356.","journal-title":"Arch Intern Med"},{"key":"460_CR31","first-page":"60","volume":"22","author":"DP Chew","year":"2002","unstructured":"Chew DP. Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures. Hamostaseologie. 2002;22:60\u20136.","journal-title":"Hamostaseologie"},{"key":"460_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/MAT.0000000000000067","volume":"60","author":"A Badiye","year":"2014","unstructured":"Badiye A, Hernandez GA, Chaparro S. Argatroban as novel therapy for suspected thrombosis in patients with continuous-flow left ventricle assist device and hemolysis. ASAIO J. 2014;60:361\u20135.","journal-title":"ASAIO J"},{"key":"460_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/BF03085963","volume":"15","author":"SS Rensen","year":"2007","unstructured":"Rensen SS, Doevendans PA, van Eys GJ. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J. 2007;15:100\u20138.","journal-title":"Neth Heart J"},{"key":"460_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0014-2999(03)01293-7","volume":"461","author":"M Yoshinaga","year":"2003","unstructured":"Yoshinaga M, Sunagawa M, Shimada S, Nakamura M, Murayama S, Kosugi T. Argatroban, specific thrombin inhibitor, induced phenotype change of cultured rabbit vascular smooth muscle cells. Eur J Pharmacol. 2003;461:9\u201317.","journal-title":"Eur J Pharmacol"},{"key":"460_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1042\/BJ20070767","volume":"408","author":"DR Croucher","year":"2007","unstructured":"Croucher DR, Saunders DN, Stillfried GE, Ranson M. A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells. Biochem J. 2007;408:203\u201310.","journal-title":"Biochem J"},{"key":"460_CR36","doi-asserted-by":"publisher","first-page":"15994","DOI":"10.1073\/pnas.0705898104","volume":"104","author":"LK Sanders","year":"2007","unstructured":"Sanders LK, Xian W, Guaqueta C, Strohman MJ, Vrasich CR, Luijten E, et al. Control of electrostatic interactions between F-actin and genetically modified lysozyme in aqueous media. Proc Natl Acad Sci USA 2007;104:15994\u20139.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00460-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00460-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00460-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T09:12:56Z","timestamp":1726218776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00460-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":36,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1038\/s41434-024-00460-2","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"type":"print","value":"0969-7128"},{"type":"electronic","value":"1476-5462"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"30 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was not required as we used cell lines for the in vitro experiments and no primary tissues or primary cell cultures were used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}